The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
A platinum(IV) analogue with antineoplastic activity. Ormaplatin
alkylates DNA, forming both inter- and intra-strand platinum-DNA
crosslinks, which result in inhibition of DNA replication and
transcription and cell-cycle nonspecific cytotoxicity.